Blood plasma goliath CSL reported reasonably well early this month but it hasn’t been enough for the market which has sent the stock slightly lower, it doesn’t help that CSL is very owned and loved on our fare shores after a decade of strong performance. On the positive side, plasma collections were strong with plasma volumes up 31% and now at records which in simple terms, provides solid inventory levels for which CSL can monetise.
- We see some further sentiment-driven downside in CSL short term but in our opinion, solid value is approaching around 6-8% lower.
MM likes CSL in the $240-250 area
Add To Hit List
